等待开盘 04-02 09:30:00 美东时间
+4.020
+5.09%
今日重点评级关注:Oppenheimer:维持Alumis"跑赢大市"评级,目标价从50美元升至55美元;美银证券:维持Rocket Pharmaceuticals"买入"评级,目标价从8美元升至9美元
03-31 16:30
Guggenheim analyst Subbu Nambi maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price target from $120 to $100.
03-30 23:28
今日重点评级关注:韦德布什:维持TScan Therapeutics"跑赢大市"评级,目标价从4美元升至5美元;HC Wainwright & Co.:维持莱斯康制药"买入"评级,目标价从4美元升至6美元
03-06 11:58
Guggenheim analyst Subbu Nambi reiterated a Buy rating on BillionToOne, Inc. Cl...
03-05 20:18
Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all changes. VEEV, GENI, DOW, BLLN, OKTA, VAC, WLK, EYPT had price target changes.
03-05 20:06
BTIG analyst Mark Massaro maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price target from $160 to $140.
03-05 18:20
The latest announcement is out from BillionToOne, Inc. Class A ( ($BLLN) ). In ...
03-05 05:42
BillionToOne (NASDAQ:BLLN) raises FY2026 sales outlook from $415.000 million-$430.000 million to $430.000 million-$445.000 million.
03-05 05:08
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-drawMENLO PARK, Calif., Feb. 10, 2026 /PRNewswire/ -- BillionToOne, Inc.
02-10 22:10